Dana-Farber Cancer Institute boasts an impressive history of key discoveries about the immune system. Their powerhouse investigators have been on the frontlines. Dana-Farber’s research revealed that a protein known as PD-L1 is expressed on normal and cancer cells, enabling cancers to evade the immune response, and that blocking PD-L1 and a related protein, PD-1, could unleash the immune attack on tumor cells. PICI scientists at Dana-Farber are leaders in immunology and contribute greatly to our research agenda. Laurie H. Glimcher, MD | Director All Investigators Related Press Release PICI, JDRF and Helmsley Trust Form Research Initiative Cancer Research Heroes, Research Update Personalized Cancer Vaccines to Conquer Cancer Research Update Personalized cancer neoantigen vaccines show success in two small studies Announcement, Press Release PICI Appoints John Connolly as Chief Scientific Officer Research Project CANDEL: A first-of-its-kind data analysis engine for scientific discovery Cancer Research Heroes, Partner Highlight A Science-Driven Partnership Announcement Our Stance on Equality Cancer Research Heroes The Power of Patient Samples Research Project REVIVE: Can we outsmart cancer by learning from the past?